Generic Biologics Bill May Not Ride FDARA But Legislators Will Keep Pushing
Executive Summary
House legislators assure the generics industry that they remain committed to generic biologics legislation, though the FDA reform bill reauthorizing the drug user fee program will move ahead without it
You may also be interested in...
Discounted “Stopgap” PDUFA Renewal Might Prompt Faster FDARA Action
A proposal circulated by House Democrats to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Senate Health, Education, Labor and Pensions Committee Ranking Republican Michael Enzi, Wyo., has declared
Discounted “Stopgap” PDUFA Renewal Might Prompt Faster FDARA Action
A proposal circulated by House Democrats to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Senate Health, Education, Labor and Pensions Committee Ranking Republican Michael Enzi, Wyo., has declared
Biosimilar “Interchangeability” Standard Is Double-Edged Sword For Generics
The interchangeability standard for follow-on biologics set out in Senate legislation creates a relatively smooth pathway for generic firms to seek approval of such products, but could also lead to an extended struggle to win acceptance for such products in the marketplace